RxDoctor Payments Data

Eric Quinones-Cordero, MD

Internal Medicine · San Juan, PRNPI 1053334201

Payments from drug & device makers

$428in general payments, 2019–2025

Across 21 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$270
  • Amgen$62
  • AstraZeneca$35
  • E.r. Squibb & Sons, L.L.C.$24
  • Pfizer Pharmaceuticals LLC$15
  • Eli Lilly Export S.A. Puerto Rico Branch$12
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$428100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK11$270
Amgen3$62
AstraZeneca2$35
E.r. Squibb & Sons, L.L.C.2$24
Pfizer Pharmaceuticals LLC1$15
Eli Lilly Export S.A. Puerto Rico Branch1$12
PBG Puerto Rico LLC1$11

How this compares

$428 in reported general payments places this provider in the 40th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$31,262
Medicare patients
58
Services billed
617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab46$338,448
ProliaDenosumab89$156,882
Orencia ClickjectAbatacept20$115,174
Xeljanz XrTofacitinib Citrate19$108,793
Humira PenAdalimumab14$95,542
Taltz AutoinjectorIxekizumab13$90,904
RinvoqUpadacitinib13$83,756
Enbrel MiniEtanercept11$82,866
Omega-3 Acid Ethyl Esters500$19,876
OzempicSemaglutide19$18,552
Diclofenac Sodium570$11,955
Diclofenac Potassium225$11,217
SynthroidLevothyroxine Sodium194$9,669
Gabapentin756$9,484
Sucralfate71$8,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$62$156,88289 claims
AstraZenecaFarxiga$35$7,13112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →